10 OVERDOSAGE

 

Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [see Warnings and Precautions ( 5.9) and Clinical Pharmacology ( 12.2)] .7.2 Potential for Other Drugs to Affect Tadalafil Tablets[See Dosage and Administration ( 2.7) and Warnings and Precautions ( 5.10)] .Antacids— Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil.H 2Antagonists (e.g.

Aspect	Details	Notes
Standard Dose	10 mg	Typically prescribed for ED
Onset of Action	30-60 minutes	Effects may vary individually
Duration of Effect	Up to 36 hours	Longer than many PDE5 inhibitors
Administration Timing	30 minutes before activity	Can be taken with or without food

Nizatidine) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.Cytochrome P450 Inhibitors— Tadalafil tablets are a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure.CYP3A4 (e.g., Ketoconazole)— Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and C maxby 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C maxby 15%, relative to the values for tadalafil 10 mg alone [see Dosage and Administration ( 2.7)] .Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.HIV Protease inhibitor— Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max, relative to the values for tadalafil 20 mg alone.

How Long Does Cialis Take to Work? How Long Should It Last?

Ritonavir (200 mg twice daily), increased tadalafil 20-mg single-dose exposure (AUC) by 124% with no change in C max, relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure [see Dosage and Administration ( 2.7)] .Cytochrome P450 Inducers— Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure.CYP3A4 (e.g., Rifampin)— Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C maxby 46%, relative to the values for tadalafil 10 mg alone.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	60mg	20 Pills	65.61€ 62.49€	Buy
Cialis Generic	10mg	180 + 8 Pills	236.88€ 225.60€	Buy
Cialis Generic	20mg	10 Pills	31.49€ 29.99€	Buy
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€	Buy
Tadalista Super Active	20mg	10 Pills	55.64€ 52.99€	Buy
Cialis Generic	2.5mg	90 + 6 Pills	112.43€ 107.08€	Buy
Cialis Generic	2.5mg	60 + 4 Pills	83.43€ 79.46€	Buy
Cialis Generic	5mg	270 + 10 Pills	205.81€ 196.01€	Buy
Tadalista Super Active	20mg	180 + 20 Pills	521.59€ 496.75€	Buy
Cialis Generic	10mg	30 + 4 Pills	63.32€ 60.30€	Buy
Cialis Generic	2.5mg	120 + 6 Pills	128.93€ 122.79€	Buy
Cialis Generic	60mg	10 Pills	41.22€ 39.26€	Buy
Cialis Generic	10mg	90 + 6 Pills	146.17€ 139.21€	Buy
Cialis Generic	40mg	120 + 8 Pills	206.98€ 197.12€	Buy
Cialis Generic	40mg	10 Pills	37.79€ 35.99€	Buy

Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure.

• Absorption is not significantly affected by age.
• Dosage adjustment is recommended for renal impairment.
• For severe renal impairment, maximum dose is 10 mg every 72 hours.
• For mild to moderate hepatic impairment, dose adjustment may not be needed.
• Not studied in severe hepatic impairment; use is not recommended.
• Elderly patients (over 65) may be more sensitive to side effects.

The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil tablets for once daily use; the magnitude of decreased efficacy is unknown.7.3 Potential for Tadalafil Tablets to Affect Other DrugsAspirin— Tadalafil did not potentiate the increase in bleeding time caused by aspirin.Cytochrome P450 Substrates— Tadalafil tablets are not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.CYP1A2 (e.g. Theophylline)— Tadalafil had no significant effect on the pharmacokinetics of theophylline. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed.CYP2C9 (e.g. Warfarin)— Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.CYP3A4 (e.g. Midazolam or Lovastatin)— Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin.P-glycoprotein (e.g. Digoxin)— Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects. Nitrates— Administration of tadalafil tablets to patients who are using any form of organic nitrate, is contraindicated. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring [see Dosage and Administration ( 2.7), Contraindications ( 4.1), and Clinical Pharmacology ( 12.2)] . Alpha-Blockers— Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. [see Dosage and Administration ( 2.7), Warnings and Precautions ( 5.6), and Clinical Pharmacology ( 12.2)] . Antihypertensives— PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. [see Warnings and Precautions ( 5.6) and Clinical Pharmacology ( 12.2)] .

What special precautions should I follow?

Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [see Warnings and Precautions ( 5.9) and Clinical Pharmacology ( 12.2)] .7.2 Potential for Other Drugs to Affect Tadalafil Tablets[See Dosage and Administration ( 2.7) and Warnings and Precautions ( 5.10)] .Antacids— Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil.H 2Antagonists (e.g. Nizatidine) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.Cytochrome P450 Inhibitors— Tadalafil tablets are a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure.CYP3A4 (e.g., Ketoconazole)— Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and C maxby 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C maxby 15%, relative to the values for tadalafil 10 mg alone [see Dosage and Administration ( 2.7)] .Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.HIV Protease inhibitor— Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max, relative to the values for tadalafil 20 mg alone.

Full Text Sources

Ritonavir (200 mg twice daily), increased tadalafil 20-mg single-dose exposure (AUC) by 124% with no change in C max, relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure [see Dosage and Administration ( 2.7)] .Cytochrome P450 Inducers— Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure.CYP3A4 (e.g., Rifampin)— Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C maxby 46%, relative to the values for tadalafil 10 mg alone. Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil tablets for once daily use; the magnitude of decreased efficacy is unknown.7.3 Potential for Tadalafil Tablets to Affect Other DrugsAspirin— Tadalafil did not potentiate the increase in bleeding time caused by aspirin.Cytochrome P450 Substrates— Tadalafil tablets are not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.CYP1A2 (e.g.

4. Medications

Theophylline)— Tadalafil had no significant effect on the pharmacokinetics of theophylline. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed.CYP2C9 (e.g. Warfarin)— Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.CYP3A4 (e.g. Midazolam or Lovastatin)— Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin.P-glycoprotein (e.g. Digoxin)— Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects. Alcohol— Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators.

Medication savings with ScriptSave® WellRx

Surviving offspring had normal development and reproductive performance.In another rat prenatal and postnatal development study at doses of 60, 200, and 1000 mg/kg, a reduction in postnatal survival of pups was observed. The no observed effect level (NOEL) for maternal toxicity was 200 mg/kg/day and for developmental toxicity was 30 mg/kg/day. This gives approximately 16 and 10 fold exposure multiples, respectively, of the human AUC for the MRHD of 20 mg.Tadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.8.2 LactationRisk SummaryTadalafil tablets are not indicated for use in females.There is no information on the presence of tadalafil and/or metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-fold greater than found in the plasma.8.3 Females and Males of Reproductive PotentialInfertilityBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months. This effect was not seen in the study of 20 mg tadalafil taken for 6 months.

Tadalafil 20 mg: How long does it last?

Oral Administration

[see Warnings and Precautions ( 5.9) and Clinical Pharmacology ( 12.2)] . [See tadalafil 2 5 mg Dosage and Administration ( 2.7) and Warnings and Precautions ( 5.10)] . Nizatidine) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.

Country	Legal Status	Prescription Required	Notes
USA	Prescription-only	Yes	Approved for ED and BPH
UK	Prescription-only	Yes	Controlled medication
Canada	Prescription-only	Yes	Available via pharmacy
Australia	Prescription-only	Yes	Schedule 4 drug
India	Prescription required	Yes	Widely available

Cytochrome P450 Inhibitors— Tadalafil tablets are a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure.

Side Effects

CYP3A4 (e.g., Ketoconazole)— Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and C maxby 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C maxby 15%, relative to the values for tadalafil 10 mg alone [see Dosage and Administration ( 2.7)] .

Parameter	Value	Description
Absorption Rate	Rapid	Peaks in about 2 hours
Bioavailability	80%	Percentage absorbed into bloodstream
Half-life	17.5 hours	How long the drug stays active
Metabolism	Liver via CYP3A4	Hepatic processing
Excretion	Feces and urine	Mainly via feces

Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure. HIV Protease inhibitor— Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max, relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure [see Dosage and Administration ( 2.7)] . Cytochrome P450 Inducers— Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure. CYP3A4 (e.g., Rifampin)— Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C maxby 46%, relative to the values for tadalafil 10 mg alone. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil tablets for once daily use; the magnitude of decreased efficacy is unknown.

• Cost-saving tip: ask for a 90-day supply if on daily therapy.
• Some insurance plans have tiered formularies affecting copay.
• Manufacturer of Cialis (Eli Lilly) may offer savings programs.
• International nonproprietary name (INN) is tadalafil.
• Patent expirations allowed for generic market entry.
• Always verify pharmacy accreditation before purchasing online.

Aspirin— Tadalafil did not potentiate the increase in bleeding time caused by aspirin.

Publication types

HIV Protease inhibitor— Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max, relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure [see Dosage and Administration ( 2.7)] . Cytochrome P450 Inducers— Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure. CYP3A4 (e.g., Rifampin)— Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C maxby 46%, relative to the values for tadalafil 10 mg alone. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil tablets for once daily use; the magnitude of decreased efficacy is unknown.

When is 60 mg of tadalafil prescribed?

Aspirin— Tadalafil did not potentiate the increase in bleeding time caused by aspirin. Cytochrome P450 Substrates— Tadalafil tablets are not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed. Warfarin)— Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.

Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis

Midazolam or Lovastatin)— Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin. 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryTadalafil is not indicated for use in females.There are no data with the use of tadalafil tablets in pregnant women to inform any drug-associated risks for adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures up to 11 times the maximum recommended human dose (MRHD) of 20 mg/day (see Data).DataAnimal DataAnimal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given orally to pregnant rats or mice at exposures up to 11 times the maximum recommended human dose (MRHD) of 20 mg/day during organogenesis. In a prenatal/postnatal developmental study in rats, postnatal pup survival decreased following maternal exposure to tadalafil doses greater than 10 times the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 16 times the MRHD based on AUC. Cytochrome P450 Substrates— Tadalafil tablets are not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.

17.8 Sudden Hearing Loss

Nitrates— Administration of tadalafil tablets to patients who are using any form of organic nitrate, is contraindicated. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring [see Dosage and Administration ( 2.7), Contraindications ( 4.1), and Clinical Pharmacology ( 12.2)] . Alpha-Blockers— Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. [see Dosage and Administration ( 2.7), Warnings and Precautions ( 5.6), and Clinical Pharmacology ( 12.2)] . Antihypertensives— PDE5 inhibitors, including tadalafil, are mild systemic vasodilators.

Muscular Dystrophy (Orphan)

[see Warnings and Precautions ( 5.6) and Clinical Pharmacology ( 12.2)] . Alcohol— Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. [see Warnings and Precautions ( 5.9) and Clinical Pharmacology ( 12.2)] . [See tadalafil 2 5 mg Dosage and Administration ( 2.7) and Warnings and Precautions ( 5.10)] . Nizatidine) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.

Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events

Cytochrome P450 Inhibitors— Tadalafil tablets are a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure. CYP3A4 (e.g., Ketoconazole)— Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and C maxby 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C maxby 15%, relative to the values for tadalafil 10 mg alone [see Dosage and Administration ( 2.7)] . Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed.

• Tadalafil 10 mg is useful for sporadic or daily erectile issues.
• Keep a medication diary to track effectiveness and side effects.
• The pill should be stored away from moisture and heat.
• Discuss with your doctor any other health conditions before use.
• Tadalafil may cause back pain in some users.
• Do not use if you are allergic to tadalafil or its ingredients.
• The drug is approved by regulatory authorities in many countries.
• An erection should only occur with sexual arousal.
• Discuss potential interactions with your healthcare provider.
• Discontinue use and seek medical attention if adverse effects occur.

Warfarin)— Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. Midazolam or Lovastatin)— Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin. 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryTadalafil is not indicated for use in females.There are no data with the use of tadalafil tablets in pregnant women to inform any drug-associated risks for adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures up to 11 times the maximum recommended human dose (MRHD) of 20 mg/day (see Data).DataAnimal DataAnimal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given orally to pregnant rats or mice at exposures up to 11 times the maximum recommended human dose (MRHD) of 20 mg/day during organogenesis. In a prenatal/postnatal developmental study in rats, postnatal pup survival decreased following maternal exposure to tadalafil doses greater than 10 times the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 16 times the MRHD based on AUC. Surviving offspring had normal development and reproductive performance.In another rat prenatal and postnatal development study at doses of 60, 200, and 1000 mg/kg, a reduction in postnatal survival of pups was observed. The no observed effect level (NOEL) for maternal toxicity was 200 mg/kg/day and for developmental toxicity was 30 mg/kg/day. This gives approximately 16 and 10 fold exposure multiples, respectively, of the human AUC for the MRHD of 20 mg.Tadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.8.2 LactationRisk SummaryTadalafil tablets are not indicated for use in females.There is no information on the presence of tadalafil and/or metabolites in human milk, the effects on the breastfed child, or the effects on milk production.

6.1 Clinical Trials Experience

Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-fold greater than found in the plasma.8.3 Females and Males of Reproductive PotentialInfertilityBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months. This effect was not seen in the study of 20 mg tadalafil taken for 6 months.

• Some men may not respond adequately to 10 mg tadalafil.
• Doctor may increase to 20 mg for on-demand use if tolerated.
• Conversely, side effects may prompt a decrease to 5 mg.
• Do not change your dose without consulting your physician.
• It may take several attempts to find the optimal dosing regimen.
• Patience and communication with your doctor are key.